Predicting Response to Lithium in Mood Disorders

Serretti, Alessandro; Artioli, Paola

doi:10.2165/00129785-200303010-00004

Cited by 27 publications

(9 citation statements)

References 209 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though therapeutic efficacy of lithium as a mood stabilizer has been shown to be associated with SLC6A4 genotypes, with better outcomes for patients with the L/L or L/S genotypes [148], most of the published pharmacogenomic studies of lithium primarily focus on the inositol turnover signaling pathway and the inhibition of glycogen synthase kinase 3-ß (GSK3B). Patients with bipolar disorder are reported to have hyperactive signaling in the inositol turnover signaling pathway, and lithium use inhibits the activity of inositol polyphosphate-1-phosphatase (INPP1) and inositol monophosphotases (IMPA1 and IMPA2), resulting in reduced amount of free inositol available for signaling activity [149].…”

Section: Mood Stabilizersmentioning

confidence: 99%

Pharmacogenomics in Psychiatric Disorders

et al. 2013

View full text Add to dashboard Cite

Section: Mood Stabilizersmentioning

confidence: 99%

Pharmacogenomics in Psychiatric Disorders

et al. 2013

View full text Add to dashboard Cite

“…A functional variant in the 5'-regulatory region of this gene is a 44 bp insertion/deletion, resulting in short (S) and long (L) alleles. The S allele decreases the transcription and transport activity of the SERT gene [Serretti and Artioli 2003] Numerous association studies have outlined that individuals carrying at least one L allele, are responding more favorable and faster to SSRIs, as fluvoxamine, paroxetine and citalopram and the S/S genotype had been associated with slower response on paroxetine, respectively nonremission in citalopram and fluvoxamine treatment. Serretti et al 2005a].…”

Section: Antidepressants: Response To Treatmentmentioning

confidence: 99%

“…lithium, which is widely used as mood stabilizer. Serretti et al have shown, that patients with the L/L or L/S genotype had a better outcome than those with the S/S variant [Serretti and Artioli 2003;Serretti et al 2005b]. …”

Section: Antidepressants: Response To Treatmentmentioning

confidence: 99%

Molecular Methods for Individualization of Psychotropic Drug Treatment

Bondy¹,

Zill

2006

CPG

View full text Add to dashboard Cite

Genetic factors are supposed to play a major role for the differences in response to treatment or the incidence of adverse drug effects in psychopharmacotherapy. The aim of pharmacogenetics is to elucidate this variability due to hereditary differences. According to the currently known hypotheses on the mechanisms of drug action, several mutations in genes coding for neurotransmitter-receptors, -degrading enzymes, transport proteins or enzymes of the drug metabolizing system have been identified and investigated in terms of efficacy and adverse drug effects. Although there exists considerable controversy among the results, many studies are supportive for the hypothesis, that psychopharmacogenetics will be helpful in predicting an individual's drug response and identify persons at risk for serious side effects on the basis of the genetic make up. The introduction and inclusion of pharmacogenomics, which is a powerful tool to identify genes affected by drugs, will most likely help to delineate so far unknown drug targets, predict drug responsiveness and adverse reactions and finally propose new hypotheses for both the pathophysiological basis of psychiatric disorders and the mechanisms of psychotropic drug action. This paper briefly overviews the present status of pharmacokinetic and pharmacodynamic aspects in the pharmacogenetics of antipsychotics, antidepressants and lithium ions. Further, a summary on the work investigating genes of the signal transduction cascade, neuronal plasticity and stress response is given.

show abstract

“…3) (26). Interessant ist auch, dass diese 5-HTT-Varianten nicht nur bei der Behandlung mit SSRIs von Bedeutung sind, sondern auch bei der Behandlung mit Lithiumionen, obwohl sie hier nicht das primäre Zielprotein der Wirkung sind (27).…”

Section: Pharmakogenetik Der Schizophrenieunclassified

Pharmakogenetik in der Psychiatrie

Bondy¹,

Zill²

2004

Nervenheilkunde

View full text Add to dashboard Cite

ZusammenfassungDer Erfolg einer Behandlung mit Psychopharmaka wird durch viele Faktoren beeinflusst, darunter auch durch Varianten von Genen, die sowohl pharmakokinetische als auch pharmakodynamische Eigenschaften der Medikamente regulieren. Obwohl die pharmakogenetische Forschung in der Psychiatrie noch in den Anfängen steht, wurde bereits deutlich, dass zumindest einigen Polymorphismen in Genen der Serotonin-Rezeptoren, des Serotonin-Transporters sowie der Dopamin-Rezeptoren eine Rolle bei der Wirkung und Nebenwirkung der Substanzen zukommt. Neuere Untersuchungen beziehen sich auf Strukturen jenseits der initialen Zielproteine der Substanzen, wie die G-Proteine, welche die Kaskade der Signaltransduktion initiieren und damit den Ausgangspunkt für eine Veränderung der Genexpression darstellen. Vor allem die neue Strategie der Pharmakogenomik mit Darstellung von Genexpressions-Profilen hat das Potenzial aufschlussreiche Einblicke in die bis heute nicht geklärten Langzeiteffekte und Wirkmechanismen von Psychopharmaka auf molekularer Ebene zu gewähren.

show abstract

Predicting Response to Lithium in Mood Disorders

Cited by 27 publications

References 209 publications

Pharmacogenomics in Psychiatric Disorders

Pharmacogenomics in Psychiatric Disorders

Molecular Methods for Individualization of Psychotropic Drug Treatment

Pharmakogenetik in der Psychiatrie

Contact Info

Product

Resources

About